Compounding no more: Ozempic and Wegovy face a regulatory reset

“The era of compounded GLP-1s is over”

Chronological Timeline of Events:

1. 2022–2024: Semaglutide Shortage and Compounding Surge
Due to skyrocketing demand for Ozempic and Wegovy, the FDA declared a shortage of semaglutide. During this period, compounding pharmacies (both 503A and 503B) legally produced compounded versions of semaglutide to help meet patient needs.

2. February 2025: FDA Declares Shortage Over
The FDA determined that semaglutide was no longer in shortage in the U.S. This decision meant that compounding pharmacies could no longer legally make compounded versions of the drug, except under very limited circumstances.

3. February 2025: Lawsuit Filed by Compounding Trade Group

In response to the FDA’s decision, the Outsourcing Facilities Association (representing 503B compounders) filed a lawsuit against the FDA. They sought a preliminary injunction to prevent the FDA from taking enforcement action against its members for continuing to make compounded semaglutide.

4. April 24, 2025: Federal Court Ruling

U.S. District Judge Mark Pittman denied the Outsourcing Facilities Association’s request for a preliminary injunction. This ruling allowed the FDA to proceed with enforcement against compounding pharmacies making copies of semaglutide.

5. April 25, 2025: Novo Nordisk’s Legal Victory Announced

News broke that Novo Nordisk, the maker of Ozempic and Wegovy, had scored a major legal win. The court’s decision largely restricts compounding pharmacies from marketing or selling unapproved, cheaper versions of these drugs.

“From shortage to scrutiny: The Ozempic/Wegovy compounding saga”

6. Immediate and Future Enforcement
Following the court’s decision:

• 503A compounding pharmacies (state-regulated, typically local pharmacies) must immediately stop compounding semaglutide.
• 503B outsourcing facilities (federally regulated, bulk manufacturers) have until May 22, 2025, to cease production and sale of compounded semaglutide.

7. Ongoing FDA Enforcement
The FDA is now empowered to take enforcement actions, such as product seizures and warning letters, against pharmacies that do not comply.

In Conclusion:

This sequence of events marks the end of widespread compounding of semaglutide, with the FDA’s regulatory authority and Novo Nordisk’s position upheld in court.

“Compounding no more: Ozempic and Wegovy face a regulatory reset”

Disclaimer: This blog post with timeline is for informational purposes only and does not constitute medical, legal, or regulatory advice. The information provided is based on publicly available sources and recent news as of the date of publication. Readers should consult healthcare professionals for medical advice and qualified legal or regulatory experts for guidance on compliance and pharmacy practices. The author and publisher are not responsible for any actions taken based on the content of this blog.